November 17, 2022

8:30 a.m. – 5:05 p.m. ET

Meeting place:

FDA White Oak Campus, Silver Spring, MD Bldg. 31 Great Hall 1503

Registration links:

Goals and Objectives:

  • To provide a forum for open discussion among stakeholders on the role of brain amyloid PET imaging in addressing an unmet public health need.
  • Seek input from industry, academia, and other stakeholders on amyloid brain PET imaging in clinical use and in clinical trials.
  • Ensure that leading experts from research universities, pharmaceutical companies, device industries, clinical trials using amyloid brain PET imaging, and the patient advocacy group have the opportunity to share recent developments among colleagues and public interest groups.
  • Facilitate open discussions between all parties in the field of imaging medicine.
  • Get feedback from multiple stakeholders on quantitative imaging approaches in patient selection, prognosis, and monitoring treatment response in clinical trials.

Who should attend:

This workshop is intended for a diverse group of scientists, responsible for evaluating quantitative positron emission tomography (PET) measurements of amyloid deposition in the brain in clinical trials and clinical use in patients with suspected or confirmed Alzheimer’s disease.

The primary audience is expected to include leading academic experts, pharmaceutical companies, patient advocacy groups, healthcare providers, clinicians, and leading scientists from the United States and abroad.


If at SNMMI:

Bonnie Clark
Senior Director Research, Discovery and Quality
Society for Nuclear Medicine and Molecular Imaging
[email protected]

If at MITA:

Susan K Bunning
Industry Director, Positron Emission Tomography
Medical imaging and technology alliance
[email protected]

If at the FDA:

Libero Marzella, MD, Ph.D.
Director, Division of Imaging and Radiation Medicine
Specialist Medicine Office
Office of New Drugs
Center for Drug Evaluation and Research
Food and drug administration
301-796-1414 ext. 1414
[email protected]